ALS patients differ on treatment choices in later phases of disease

In two new studies analyzing treatment decisions in late-stage amyotrophic lateral sclerosis (ALS) patients, researchers from the Perelman School of Medicine at the University of Pennsylvania found that delaying one treatment resulted in not living long enough to experience the benefits. They also uncovered polarized preferences among patients regarding the value of an expensive, marginally effective disease-modifying drug. The research will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans. Read more